Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IONS |
---|---|---|
09:32 ET | 14628 | 39.32 |
09:34 ET | 4177 | 39.23 |
09:36 ET | 1200 | 39.53 |
09:38 ET | 630 | 39.235 |
09:39 ET | 1300 | 39.105 |
09:41 ET | 800 | 39.01 |
09:43 ET | 4189 | 39.04 |
09:45 ET | 19057 | 39.29 |
09:48 ET | 1345 | 39.2 |
09:50 ET | 1213 | 39.3 |
09:52 ET | 600 | 39.42 |
09:54 ET | 3276 | 39.59 |
09:56 ET | 3257 | 39.565 |
09:57 ET | 1857 | 39.595 |
09:59 ET | 700 | 39.55 |
10:01 ET | 2725 | 39.4 |
10:03 ET | 2150 | 39.25 |
10:06 ET | 41498 | 39.31 |
10:08 ET | 1400 | 39.43 |
10:10 ET | 500 | 39.355 |
10:12 ET | 1612 | 39.37 |
10:14 ET | 100 | 39.39 |
10:15 ET | 2757 | 39.52 |
10:17 ET | 1800 | 39.75 |
10:19 ET | 808 | 39.64 |
10:21 ET | 680 | 39.55 |
10:24 ET | 2000 | 39.595 |
10:26 ET | 500 | 39.62 |
10:28 ET | 900 | 39.5 |
10:30 ET | 1000 | 39.67 |
10:32 ET | 1500 | 39.71 |
10:33 ET | 722 | 39.755 |
10:35 ET | 674 | 39.7502 |
10:37 ET | 700 | 39.66 |
10:39 ET | 2240 | 39.63 |
10:42 ET | 500 | 39.535 |
10:44 ET | 1165 | 39.53 |
10:46 ET | 22965 | 39.625 |
10:48 ET | 1700 | 39.64 |
10:50 ET | 500 | 39.78 |
10:51 ET | 1733 | 39.74 |
10:53 ET | 6391 | 39.69 |
10:55 ET | 830 | 39.69 |
10:57 ET | 1200 | 39.715 |
11:00 ET | 2750 | 39.62 |
11:02 ET | 400 | 39.72 |
11:04 ET | 200 | 39.7 |
11:06 ET | 1305 | 39.6825 |
11:08 ET | 200 | 39.67 |
11:09 ET | 300 | 39.61 |
11:11 ET | 400 | 39.57 |
11:13 ET | 6062 | 39.485 |
11:15 ET | 3577 | 39.42 |
11:18 ET | 62563 | 39.4 |
11:20 ET | 58981 | 39.215 |
11:22 ET | 999 | 39.29 |
11:24 ET | 3000 | 39.28 |
11:26 ET | 900 | 39.46 |
11:27 ET | 1000 | 39.37 |
11:29 ET | 300 | 39.405 |
11:31 ET | 1450 | 39.4 |
11:33 ET | 200 | 39.415 |
11:36 ET | 24949 | 39.49 |
11:38 ET | 158307 | 39.38 |
11:40 ET | 3719 | 39.42 |
11:42 ET | 302 | 39.425 |
11:44 ET | 907 | 39.3776 |
11:47 ET | 200 | 39.33 |
11:49 ET | 54093 | 39.11 |
11:51 ET | 1992 | 39.09 |
11:54 ET | 400 | 39.16 |
11:56 ET | 241 | 39.23 |
11:58 ET | 1801 | 39.15 |
12:00 ET | 200 | 39.065 |
12:02 ET | 500 | 39.03 |
12:03 ET | 1200 | 39.116 |
12:05 ET | 458 | 39.1 |
12:07 ET | 800 | 39.18 |
12:09 ET | 900 | 39.15 |
12:12 ET | 2414 | 39.12 |
12:14 ET | 1200 | 39.18 |
12:16 ET | 670 | 39.15 |
12:18 ET | 1265 | 39.13 |
12:20 ET | 903 | 39.16 |
12:21 ET | 1451 | 39.25 |
12:23 ET | 1433 | 39.35 |
12:25 ET | 540 | 39.395 |
12:27 ET | 1621 | 39.33 |
12:30 ET | 867 | 39.33 |
12:32 ET | 1000 | 39.2 |
12:34 ET | 800 | 39.31 |
12:36 ET | 202 | 39.3 |
12:38 ET | 500 | 39.325 |
12:39 ET | 800 | 39.29 |
12:41 ET | 700 | 39.255 |
12:43 ET | 1900 | 39.25 |
12:45 ET | 800 | 39.29 |
12:48 ET | 800 | 39.26 |
12:50 ET | 200 | 39.185 |
12:52 ET | 300 | 39.205 |
12:54 ET | 2600 | 39.17 |
12:56 ET | 52000 | 39.31 |
12:57 ET | 658 | 39.32 |
12:59 ET | 700 | 39.34 |
01:01 ET | 400 | 39.29 |
01:03 ET | 500 | 39.29 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Ionis Pharmaceuticals Inc | 5.6B | -1,423.0x | --- |
Sarepta Therapeutics Inc | 6.2B | -17.1x | --- |
Azenta Inc | 5.2B | -225.7x | --- |
CRISPR Therapeutics AG | 4.4B | 15.2x | --- |
Halozyme Therapeutics Inc | 6.1B | 14.9x | --- |
Alkermes Plc | 4.9B | -77.4x | --- |
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on our cardiovascular and neurology franchises. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for the treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients. The Company has over six medicines in Phase III studies for eight indications, which include Eplontersen (TTR), Olezarsen (ApoC-III), Donidalorsen (PKK), ION363 (FUS), Pelacarsen (Apo(a)) and Tofersen (SOD1). Its cardiovascular medicine in development includes Eplontersen, Olezarsen, Pelacarsen, ION449 (PCSK9), Fesomersen and IONIS-AGT-LRx.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.6B |
---|---|
Revenue (TTM) | $840.8M |
Shares Outstanding | 141.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.71 |
EPS | $-0.03 |
Book Value | $5.47 |
P/E Ratio | -1,423.0x |
Price/Sales (TTM) | 6.7 |
Price/Cash Flow (TTM) | 406.4x |
Operating Margin | -0.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.